

RELEXXII - (18MG, 27MG, 36MG, 45MG, 54MG, 63MG, 72MG ; TABLET,EXTENDED RELEASE)

| | | | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | METHYLPHENIDATE HYDROCHLORIDE | Innovator | Osmotica |
| Dosage | 18MG, 27MG, 36MG, 45MG, 54MG, 63MG, 72MG ; TABLET,EXTENDED RELEASE | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | RELEXXII® is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.